Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

184.39
-1.7500-0.94%
Volume:1.03M
Turnover:191.41M
Market Cap:9.66B
PE:-48.93
High:188.00
Open:186.51
Low:184.00
Close:186.14
52wk High:260.19
52wk Low:117.30
Shares:52.38M
Float Shares:43.83M
Volume Ratio:1.17
T/O Rate:2.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7685
EPS(LYR):-3.6821
ROE:-245.10%
ROA:-16.31%
PB:115.94
PE(LYR):-50.08

Loading ...

Axsome Therapeutics (AXSM) Is Up 11.1% After FDA Clears AUVELITY For Alzheimer’s Agitation Treatment

Simply Wall St.
·
May 04

Axsome Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
May 02

Axsome Therapeutics price target raised to $255 from $215 at TD Cowen

TIPRANKS
·
May 01

Axsome Therapeutics Inc : TD Cowen Raises Target Price to $255 From $215

THOMSON REUTERS
·
May 01

Axsome Therapeutics Hosts Auvelity® FDA Approval Investor Event Featuring Expert Thought Leader

THOMSON REUTERS
·
May 01

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
May 01

U.S. RESEARCH ROUNDUP-Caterpillar, Textron, Wesco International

Reuters
·
May 01

Assessing Axsome Therapeutics (AXSM) Valuation After Recent Share Price Momentum

Simply Wall St.
·
May 01

Axsome Therapeutics price target raised to $217 from $207 at Morgan Stanley

TIPRANKS
·
May 01

Axsome Therapeutics given ‘clean label’ for Auvelity in ADA, says TD Cowen

TIPRANKS
·
May 01

US FDA approves Axsome's drug for Alzheimer's-related agitation

Reuters
·
May 01

Axsome Therapeutics Announces FDA Approval of Auvelity® (Dextromethorphan Hbr and Bupropion Hcl) for the Treatment of Agitation Associated With Dementia Due to Alzheimer’s Disease

THOMSON REUTERS
·
May 01

NASDAQ TRADE HALT HALT NEWS PENDING AT 02:03 PM

Reuters
·
May 01

Mizuho Securities Adjusts Axsome Therapeutics Price Target to $228 From $230, Maintains Outperform Rating

MT Newswires Live
·
Apr 28

Axsome Therapeutics Inc : Mizuho Cuts Target Price to $228 From $230

THOMSON REUTERS
·
Apr 28

Earnings Preview: Axsome Therapeutics revenue is expected to increase by 59.11%, and institutional views are broadly bullish

Earnings Agent
·
Apr 27

Axsome Therapeutics announces annual shareholder meeting via virtual webcast

Reuters
·
Apr 25

Axsome Chief Commercial Officer Ari Maizel disposes of common shares worth $1.37 million

Reuters
·
Apr 24

Axsome Therapeutics Facing 'Attractive Setup' Ahead of Auvelity's Label Expansion Decision, Oppenheimer Says

MT Newswires Live
·
Apr 21

Axsome Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
Apr 11